TITLE

TopiVert Getting $12.5M for Topical Kinase Inhibitors

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
December 2011
SOURCE
BioWorld International;12/7/2011, Vol. 16 Issue 49, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the commitment given by investors Imperial Innovations Group plc and SV Life Sciences to TopiVert Ltd., a company which focused on the discovery of topical kinase inhibitors for inflammatory conditions of the eye and gut. TopiVert has licensed intellectual property from RespiVert and will enter a drug discovery partnership with the same company. Initial areas of research of TopiVert are inflammatory bowel disease and uveitis.
ACCESSION #
70058713

 

Related Articles

  • New tech transfer models gain traction with deal flow. Hodgson, John // Nature Biotechnology;Jul2010, Vol. 28 Issue 7, p634 

    The article reports on the acquisition of respiratory drug discovery company Respivert by Centocor Ortho Biotech. Imperial Innovations sold its 13.4% stake in Respivert for 9.5 million pounds in cash. Other investors who profited from the sale include SV Life Sciences, Advent Venture Partners,...

  • RespiVert Investors Get Clean Exit in Purchase by Centocor. Moran, Nuala // BioWorld International;6/2/2010, Vol. 15 Issue 22, p1 

    The article reports on the acquisition of RespiVert Ltd. by Centocor Ortho Biotech Inc. Imperial Innovations PLC, the technology transfer arm of Imperial College which held a 13.4% stake in the company, will receive 9.5 million British pounds from the transaction. Other investors in the venture...

  • ESBATech's Series B Adds $22M for Antibody Fragment Pipeline. Boggs, Jennifer // BioWorld Today;8/7/2008, Vol. 19 Issue 153, p1 

    The article reports that Swiss company ESBATech AG has added a US$22 million investment to support ongoing work with its antibody fragment pipeline. The entry notes that a total of $86 million has been gathered from a pool of global investors which includes SV Life Sciences, Clarus Ventures, and...

  • AcuFocus raises $65M to support KAMRA inlay.  // Medical Device Daily;11/30/2011, Vol. 15 Issue 228, p2 

    The article reports on the closure of a 65 million U.S. dollars financing round by AcuFocus led by Cowen Healthcare Royalty Partners. The round was participated in by existing investors namely, SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures, and Bausch & Lomb, with...

  • KalVista Launches with $13.1M To Back DME Treatment R&D. Moran, Nuala // BioWorld International;8/24/2011, Vol. 16 Issue 34, p1 

    This article reports that a total of 8 million British pounds has been raised by Vantia Therapeutics Ltd. for the development of a portfolio of plasma kallikrein inhibitors which it will spin-out into a new company called KalVista Pharmaceuticals Ltd. The funds come from Novo Ventures and SV...

  • Financings Roundup.  // BioWorld Today;11/21/2008, Vol. 19 Issue 228, p2 

    The article reports on a Series C round of financing closed by Adimab Inc. with new investors OrbiMed Advisors and Borealis Ventures, as well as with existing investors Polaris Venture Partners and SV Life Sciences. According to Adimab, the proceeds of the financing will be used to increase its...

  • ESBATech's Series B Adds $22M for Antibody Fragment Pipeline. Boggs, Jennifer // BioWorld International;8/13/2008, Vol. 13 Issue 33, p5 

    The article reports on the additional investments achieved by ESBATech AG in August 2008 to support ongoing work with its antibody fragment pipeline. Investors included SV Life Sciences, Clarus Ventures and HBM BioVentures, among others. ESBATech is reportedly involved in the manufacture of...

  • SV Life Sciences raises over $523M in fifth funding round.  // Medical Device Daily;6/30/2010, Vol. 14 Issue 125, p2 

    The article reports that SV Life Sciences has closed its SV Life Sciences Fund V.

  • Midwest.  // Ophthalmology Times;10/9/95, Vol. 20 Issue 39, p6 

    Reports that Laser Vision Centers Inc. has signed a letter of commitment to make Schroder Ventures Life Sciences the lead investor in an $18 million private placement of convertible preferred stock.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics